Disclosure Of Effect Of Changes In Foreign Exchange Rates [Text Block]

OSE Immunotherapeutics - Filing #2813125

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31
Disclosure of effect of changes in foreign exchange rates [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when currency is not exchangeable into another currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of information when foreign operation’s functional currency is not exchangeable into presentation currency [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of summarised financial information about foreign operation [abstract]
Disclosure of summarised financial information about foreign operation [line items]
Non-current assets	54 581 EUR	—	—	—	—	—	—	57 670 EUR	—	—	—	—	—	—
Current assets	37 200 EUR	—	—	—	—	—	—	44 206 EUR	—	—	—	—	—	—
Non-current liabilities	42 856 EUR	—	—	—	—	—	—	37 224 EUR	—	—	—	—	—	—
Current liabilities	16 268 EUR	—	—	—	—	—	—	16 761 EUR	—	—	—	—	—	—
Revenue	—	—	—	18 302 EUR	—	—	—	—	—	—	—	—	—	26 306 EUR
Profit (loss)	—	—	—	17 760 EUR	—	—	17 760 EUR	—	16 850 EUR	—	—	—	—	16 850 EUR
Other comprehensive income	—	—	—	61,000 EUR	—	—	—	—	—	—	—	—	—	29,000 EUR
Comprehensive income	—	0 EUR	0 EUR	17 699 EUR	0 EUR	61,000 EUR	17 638 EUR	—	16 825 EUR	0 EUR	0 EUR	0 EUR	55,000 EUR	16 879 EUR